(2026). Comprehensive post-marketing safety evaluation of atezolizumab: A disproportionality analysis based on individual case safety reports in the FAERS. PLOS ONE.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Comprehensive Post-marketing Safety Evaluation of Atezolizumab: A Disproportionality Analysis Based on Individual Case Safety Reports in the FAERS."
PLOS ONE 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Comprehensive Post-marketing Safety Evaluation of Atezolizumab: A Disproportionality Analysis Based on Individual Case Safety Reports in the FAERS."
PLOS ONE, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.